Imidex, a Denver-based AI medical imaging software developer, has announced that it aims to sell its company to a buyer attending RSNA 2024.
The company is touting its U.S. Food and Drug Administration (FDA) 501(k)-cleared VisiRad XR AI software, which is designed to identify incidental lung nodules in lung cancer screening examinations.